Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.
van Hoogenhuijze
J
J
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Lankelma
J
J
Stam
J
J
Pinedo
H M
HM
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000378:metabolism*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide